- Revenue Growth Q4 revenue reached $12.21B (+7% YoY), with full-year revenue at $44.56B (+4% YoY).
- Adjusted EPS Growth Q4 adjusted EPS hit $6.57 (+8% YoY), and full-year adjusted EPS was $22.87 (+5% YoY).
- 2026 Guidance Revenue projected at $46.3B–$47.2B (+4%–6%), with adjusted EPS of $24.22–$24.80 (+6%–8%) assuming 3%–4% organic growth.
- Segment Performance Life Science Solutions grew 13% in Q4 (4% organic), while Analytical Instruments saw flat organic growth but optimism around AI integration.
- Capital Deployment $16.5B deployed in 2025, including $13B in M&A, and $3B in share buybacks completed in January 2026.
Segment Performance
The Life Science Solutions segment drove growth, with Q4 reported revenue increasing 13% versus the prior year quarter, and organic revenue growth of 4%, led by the bioproduction business. In contrast, the Analytical Instrument segment reported revenue increased 1%, with flat organic revenue growth. The pharma and biotech end market delivered high single-digit growth in Q4, while academic and government declined in the low single digits.
Guidance and Outlook
For 2026, Thermo Fisher Scientific initiated a revenue guidance range of $46.3 billion to $47.2 billion, representing 4% to 6% reported revenue growth, and an adjusted EPS guidance range of $24.22 to $24.80 per share, indicating 6% to 8% growth. The guidance assumes 3% to 4% organic revenue growth and a $300 million revenue tailwind from foreign exchange. Analysts estimate revenue growth at 5.2% for the next year, slightly above the company's guidance.
Valuation
With a P/E Ratio of 32.4 and an EV/EBITDA of 21.86, Thermo Fisher Scientific's valuation appears to reflect a premium for its strong growth prospects and dominant position in the life sciences industry. The company's ROE of 13.14% and ROIC of 7.5% indicate a solid return on equity and invested capital. The dividend yield of 0.3% and free cash flow yield of 2.89% provide a relatively stable return for investors.
Operational Highlights
Thermo Fisher Scientific continued to advance its growth strategy, launching several high-impact products, including the Thermo Scientific Orbitrap Astral and the Thermo Scientific five-liter DynaDrive single-use bioreactor. The company also expanded its US drug product manufacturing footprint through the acquisition of Sanofi's state-of-the-art sterile fill finish site. As Marc Casper noted, "We meaningfully advanced the position of the company, becoming even more relevant for our customers, and enhancing our competitive position."